top of page
Search Results

266 items found for "drug repurposing"

  • 📰 GPCR Weekly News, January 23 to 29, 2023

    GPCR Binders, Drugs, and more MRAP2 regulates energy homeostasis by promoting primary cilia localization GPCR Signaling Measurement and Drug Profiling with an Automated Live-Cell Microscopy System. Deadline February 12, 2023 GPCR Events, Meetings, and Webinars 2nd GPCR-Targeted Drug Discovery Summit Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.

  • 📰 GPCR Weekly News

    expressed in CA1 hippocampal neurons, selectively reduces CaV 3.2 and CaV 3.3 currents GPCR Binders, Drugs GPCR Events, Meetings, and Webinars 2nd GPCR-Targeted Drug Discovery Summit | February 21-23, Boston. Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.

  • 📰 GPCR Weekly News, October 9 to 15, 2023

    non-pheromone GPCR is essential for meiosis and ascosporogenesis in the wheat scab fungus GPCR Binders, Drugs Ozempic kidney trial after early signs of success Sosei and PharmEnable extend neurological disease drugs Intelligence Awards Japan 2023 Salipro Biotech and Icosagen Launch Antibody Discovery Collaboration Cryo-EM in Drug

  • 📰 GPCR Weekly News, July 10 to 16, 2023

    GPCR Binders, Drugs, and more Allosteric modulator potentiates β2AR agonist-promoted bronchoprotection Methods & Updates in GPCR Research Evaluation of Drug Responses to Human β2AR Using Native Mass Spectrometry NEW MPGPCR Conference (November 15 -17, 2023) Structure, Mechanism, and Drug Interactions of GPCRs, Ion

  • Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for...

    SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug developing novel oral gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) drug

  • 📰 GPCR Weekly News, March 20 to 26, 2023

    GPCR Binders, Drugs, and more A snake toxin as a theranostic agent for the type 2 vasopressin receptor (March 30, 2023) NEW Webinar - Antiverse: Engineering the Future of Drug Discovery (March 30, 2023) NEW Molecular Dynamics in Pharma (March 31, 2023) NEW FREE Workshop - Challenges in GPCR Drug Discovery Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.

  • 📰 GPCR Weekly News, June 26 to July 2, 2023

    Endocrinology, and Taste Adipocyte G Protein-Coupled Receptors as Potential Targets for Novel Antidiabetic Drugs G protein-coupled receptor-targeting antibody-drug conjugates: Current status and future directions. Structural and Molecular Insights into GPCR Function Identification of a potential structure-based GPCR drug Structure, Mechanism, and Drug Interactions of GPCRs, Ion Channels, and Transport Proteins (March 24

  • Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of...

    systems pharmacology (QSP) modeling is an emerging mechanistic computational approach that couples drug It has begun to play important roles in drug development for complex diseases such as cancer, including

  • Illuminating GPCR Research: FRET and BRET-Based Sensors Shed Light on Cellular Signaling

    mobilization, and ERK phosphorylation have been pivotal in deciphering GPCR activity, particularly in drug ability to provide real-time readouts of pharmacological activity, allowing for the determination of drug kinetics—a critical aspect in drug development [14]. our understanding of fundamental cellular processes, but also hold immense promise in accelerating drug

  • 📰 GPCR Weekly News, August 7 to 13, 2023

    Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug ) Discovery On Target - DOT (September 25 - 28, 2023) Training Seminar "The Renaissance in GPCRs as Drug November 15 -17, 2023) ASCEPT Annual Scientific Meeting (November 20 -23, 2023) Structure, Mechanism, and Drug

  • 📰 GPCR Weekly News, December 18 to 31, 2023

    Scylla paramamosain Reshaping the yeast galactose regulon via GPCR signaling cascade GPCR Binders, Drugs Research Direct Binding Methods to Measure Receptor-Ligand Interactions How accurately can one predict drug Exhibition February 11 - 14, 2024 | 2024 BPS Annual Meeting March 5 - 7, 2024 | 3rd GPCRs - Targeted Drug 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference April 1 - 4, 2024 | 19th Annual Drug

  • Structural basis for receptor selectivity and inverse agonism in S1P5 receptors

    Several S1PR therapeutic drugs have been developed to treat these diseases; however, they lack receptor sub-pocket, which clarifies the receptor subtype selectivity and provides a template for structure-based drug

  • Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies

    cancer therapies focuses on processes such as angiogenesis, cell signaling, stemness, metastasis, and drug Moreover, the use of propranolol in combination therapies with other drugs has shown synergistic antitumor

  • Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine...

    in TMC Score of 3.2 Units in Valbenazine-Treated Patients- Company Plans to Submit Supplemental New Drug Food and Drug Administration in 2022 SAN DIEGO, Dec. 7, 2021 /PRNewswire/ -- Neurocrine Biosciences (

  • Ermium Therapeutics has constituted its SAB

    of a Scientific Advisory Board comprising international leaders in GPCRs pharmacology, immunology, drug

  • 📰 GPCR Weekly News, December 11 to 17, 2023

    of the cannabinoid receptor 1-arrestin complex unravels the biased signaling mechanism GPCR Binders, Drugs Agreement with Bridge Biotherapeutics in Idiopathic Pulmonary Fibrosis Former execs from Pfizer obesity drug Exhibition February 11 - 14, 2024 | 2024 BPS Annual Meeting March 5 - 7, 2024 | 3rd GPCRs - Targeted Drug 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference April 1 - 4, 2024 | 19th Annual Drug

  • 📰 GPCR Weekly News, April 17 to 23, 2023

    GPCR Binders, Drugs, and more Development of a 5-HT7 receptor antibody for the rat: the good, the bad Presented at AACR 2023 Highlights Exscientia’s Clinical and Preclinical Development The pathway of opioid drugs Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.

  • 📰 GPCR Weekly News, April 24 to 30, 2023

    GPCR Binders, Drugs, and more Allosteric modulation of a human odorant receptor. Bioorthogonal Tethering Enhances Drug Fragment Affinity for G Protein-Coupled Receptors in Live Cells Reviews, GPCRs, and more G protein-coupled receptor-targeting antibody-drug conjugates: Current status Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.

  • GPCRS: AN ODYSSEY FROM STRUCTURE, SIGNALING AND REGULATION TO THERAPEUTICS

    highly diverse range of chemical stimuli, they represent the therapeutic targets for many existing drugs New approaches to GPCR drug discovery. in order to leverage the recent advances in the field towards new discoveries and solutions in GPCR drug

  • 📰 GPCR Weekly News, March 4 to 10, 2024

    Terry Kenakin's "Applying Pharmacology to Drug Discovery" course at Dr. Deciphering the role of GPCRs in obesity pathology for drug development GPCR Events, Meetings, and Webinars 24 - 29, 2024 | Ligand Recognition and Molecular Gating Conference April 1 - 4, 2024 | 19th Annual Drug

  • Pharmacophore-guided Virtual Screening to Identify New β 3 -adrenergic Receptor Agonists

    However, these drugs show adverse effects, including increased blood pressure in mirabegron patients. Hence, new β3 -AR agonists are needed as starting points for drug development.

  • Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic ...

    GPCRs represent major drug targets, as indicated by the fact that about 40% of all drugs currently used stellate cells (HSCs), the primary cells that regulate liver fibrosis, may lead to the development of drugs

  • 📰 GPCR Weekly News, May 29 to June 4, 2023

    GPCR Binders, Drugs, and more ACE2 Activation by Tripeptide IRW (Ile-Arg-Trp) Depends on the G Protein-Coupled Ions Regulating Agonist and Antagonist Binding in the Active Site of a Novel Target 5HT2BR Against Drug-Resistant Activity Models of Key GPCR Families in the Central Nervous System: A Tool for Many Purposes. GPCR Events, Meetings, and Webinars FREE Symposium - IPI Surfacing (June 15, 2023) GPCRs in drug discovery

  • RGS7-ATF3-Tip60 Complex Promotes Hepatic Steatosis and Fibrosis by Directly Inducing TNFα

    underlying non-alcoholic fatty liver disease (NAFLD) have yet to be fully delineated and only a single drug

  • 📰 GPCR Weekly News

    GPCR Binders, Drugs, and more Altered signaling at the PTH receptor via modified agonist contacts with Establishment of a CaCC-based Cell Model and Method for High-throughput Screening of M3 Receptor Drugs GPCR Events, Meetings, and Webinars 2nd GPCR-Targeted Drug Discovery Summit | February 21-23, Boston. Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.

  • 📰 GPCR Weekly News, June 5 to 11, 2023

    GPCR Binders, Drugs, and more Adenosine A2A Receptor (A2AAR) Ligand Screening Using the 19F-NMR Probe GPCR Events, Meetings, and Webinars GPCRs in drug discovery: challenges & solutions (June 19 - 23, 2023 I-GPCRNet (October 25 - 27, 2023) GPCR Retreat (November 2 - 4, 2023) NEW Structure, Mechanism, and Drug

  • 📰 GPCR Weekly News, January 16 to 22, 2023

    Christopher Prior, as CEO and Reports Recent Drug Discovery Highlights Call for GPCR Papers GPCRs: Signal GPCR Events, Meetings, and Webinars 2nd GPCR-Targeted Drug Discovery Summit, (February 21 - 23, 2023) Progressive Technologies and Approaches Revealing Novel GPCR Biology and Drug Development Potential.

  • ShouTi Introduces Basecamp Bio as a Wholly Owned Subsidiary to Expand Pipeline and Partnerships

    introduced Basecamp Bio, a wholly owned subsidiary dedicated to fueling ShouTi ’s pipeline and pursuing drug

bottom of page